GCP
IRON icon

GSA Capital Partners’s Disc Medicine IRON Stock Holding History

GSA Capital Partners’s Portfolio IRON Stock Details IRON Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-3,287
Closed -$261K – 1938
2025
Q4 		$261K Buy
+3,287
New +$278K 0.02% 1248

Other funds holding IRON

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

GSA Capital Partners's IRON Position: Q1 2026 in Review

GSA Capital Partners sold out of Disc Medicine (IRON) in Q1 2026, closing a stake of 3,287 shares — an estimated $261K sold.

GSA Capital Partners first reported a position in IRON in Q4 2025 and held it in 1 quarter. The position peaked at $261K in Q4 2025. 203 funds tracked by Wall St. Rank hold IRON as of Q1 2026.

  • GSA Capital Partners reported no remaining Disc Medicine position as of Q1 2026 after selling out during the quarter.
  • GSA Capital Partners sold 3,287 Disc Medicine shares in Q1 2026, an estimated $261K.
  • GSA Capital Partners first reported a position in Disc Medicine in Q4 2025 and held it in 1 quarter.
  • GSA Capital Partners's Disc Medicine position peaked at $261K in Q4 2025.
  • 203 funds tracked by Wall St. Rank held Disc Medicine as of Q1 2026.

Based on GSA Capital Partners's 13F filing for Q1 2026, filed 8 May 2026.